Ulie, 2025)
Nadeem D, Taye M, Still MD et al (2024) Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients
Methods In this retrospective cohort study, 125 474 adults with overweight or obesity newly initiated treatment with a dual-labeled GLP-1 RA (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023, with a baseline body mass index of 27 or more, an available weight measurement within 60 days before initiation, and regular care in the year before initiation were identified using electronic health record data from a collective of US health care systems
This route bypasses the digestive system, which is critical for a peptide like tirzepatide that would be destroyed by stomach acid and digestive enzymes if swallowed
Parthasarathy G, Kudva YC, Low PA, et al